Sacubitril-valsartan in patients with NT-proBNP levels outrange of PARADIGM-HF trial inclusion criteria

被引：0
|
作者：
Mario Galvan Ruiz, M. [1 ]
Fernandez De Sanmamed Giron, M. [1 ]
Singh, M. [1 ]
Groba Marco, M. V. [1 ]
Davila Ramos, M. [2 ]
Lopez Perez, M. [1 ]
Hernandez Meneses, B. [1 ]
Godoy Camacho, C. [1 ]
Martin Lorenzo, P. [1 ]
Cardenes Leon, A. [1 ]
Bujanda Morun, P. [1 ]
Perez Nogales, E. D. [3 ]
Medina Gil, J. M. [3 ]
Caballero Dorta, E. [1 ]
Garcia Quintana, A. [1 ]
机构：
[1] Univ Hosp Dr Negrin, Las Palmas Gran Canaria, Spain
[2] Univ Hosp Nuestra Seora Candelaria, Santa Cruz De Tenerife, Spain
[3] Univ Hosp Insular Gran Canaria, Las Palmas Gran Canaria, Spain
来源：
EUROPEAN JOURNAL OF HEART FAILURE | 2020年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P587
引用
收藏
页码：112 / 113
页数：2
相关论文
共 50 条
  • [41] NT-proBNP levels in diabetic cardiomyopathy: results from the ARISE-HF trial
    Butler, J.
    Tang, W. H. Wilson
    Lam, C.
    Del Prato, S.
    Ezekowitz, J.
    Ibrahim, N.
    Marwick, T.
    Perfetti, R.
    Rosenstock, J.
    Urbinati, A. Alessia
    Zannad, F.
    Januzzi, J.
    EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 : 141 - 141
  • [42] NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction TRANSITION Study
    Pascual-Figal, Domingo
    Wachter, Rolf
    Senni, Michele
    Bao, Weibin
    Noe, Adele
    Schwende, Heike
    Butylin, Dmytro
    Prescott, Margaret F.
    JACC-HEART FAILURE, 2020, 8 (10) : 822 - 833
  • [43] COST-EFFECTIVENESS OF SACUBITRIL-VALSARTAN IN CHRONIC HEART FAILURE AT EJECTION FRACTION RANGES BELOW NORMAL: A POOLED ANALYSIS FROM PARADIGM-HF AND PARAGON-HF.
    Bhatt, Ankeet
    Claggett, Brian
    Vaduganathan, Muthiah
    Desai, Akshay S.
    Shen, Xian
    Cristino, Joaquim
    McMurray, John J. V.
    Solomon, Scott D.
    Gaziano, Thomas Andrew
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 79 (09) : 382 - 382
  • [44] Clinical Role of Sacubitril/valsartan Therapy in Heart Failure With Reduced Ejection Fraction Patients With End Stage of Renal Disease; Beyond PARADIGM-HF Trial
    Lee, Seonhwa
    Oh, Jaewon
    Ha, Jaehyung
    Chun, Kyeong-Hyeon
    Kim, Hyoeun
    Lee, Chan Joo
    Park, Sungha
    Lee, Sang-Hak
    Kang, Seok-Min
    CIRCULATION, 2019, 140
  • [45] Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial
    Seferovic, Jelena P.
    Claggett, Brian
    Seidelmann, Sara B.
    Seely, Ellen W.
    Packer, Milton
    Zile, Michael R.
    Rouleau, Jean L.
    Swedberg, Karl
    Lefkowitz, Martin
    Shi, Victor C.
    Desai, Akshay S.
    McMurray, John J. V.
    Solomon, Scott D.
    LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (05): : 333 - 340
  • [46] The Association Between Congestion and Outcomes for Patients Treated With Sacubitril-Valsartan Compared to Enalapril in the PIONEER-HF Trial
    Samsky, Marc D.
    Velazquez, Eric J.
    Braunwald, Eugene
    Morrow, David A.
    Mulder, Hillary
    Chakraborty, Hrishikesh
    Duffy, Carol
    Rocha, Ricardo
    Ambrosy, Andrew P.
    Devore, Adam D.
    CIRCULATION, 2019, 140
  • [47] Racial and ethnic differences in NT-proBNP concentrations and reverse cardiac remodeling in patients with systolic heart failure treated with sacubitril/valsartan
    Ibrahim, N. Nasrien
    Pina, I. L.
    Camacho, A.
    Bapat, D.
    Butler, J.
    Felker, G. M.
    Maisel, A. S.
    Prescott, M. F.
    Abbass, C. A.
    Solomon, S. D.
    Januzzi, J. L.
    EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 : 94 - 94
  • [48] Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial
    Bouabdallaoui, Nadia
    Claggett, Brian
    Zile, Michael R.
    McMurray, John J. V.
    O'Meara, Eileen
    Packer, Milton
    Prescott, Margarett F.
    Swedberg, Karl
    Solomon, Scott D.
    Rouleau, Jean L.
    EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 (12) : 1701 - 1709
  • [49] DECLINE IN ESTIMATED GLOMERULAR FILTRATION RATE FOLLOWING SACUBITRIL/VALSARTAN INITIATION IN PATIENTS WITH HEART FAILURE: INSIGHTS FROM PARAGON-HF AND PARADIGM-HF
    Chatur, Safia
    Vaduganathan, Muthiah
    Claggett, Brian
    Mc Causland, Finnian
    Rouleau, Jean L.
    Zile, Michael R.
    Packer, Milton
    Pfeffer, Marc A.
    Lefkowitz, Martin
    McMurray, John J. V.
    Solomon, Scott D.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 276 - 276
  • [50] Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial
    Morrow, David A.
    Velazquez, Eric J.
    DeVore, Adam D.
    Prescott, Margaret F.
    Duffy, Carol, I
    Gurmu, Yared
    McCague, Kevin
    Rocha, Ricardo
    Braunwald, Eugene
    EUROPEAN HEART JOURNAL, 2019, 40 (40) : 3345 - 3352
12345